Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers of Weekly Brodalumab in Hidradenitis Suppurativa
NCT04979520Phase 1Completed
- Sponsor
- The Rockefeller University
- Start
- Aug 2021
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brodalumab in hidradenitis suppurativa (HS), sponsored by The Rockefeller University. Primary endpoint: Interleukin-17 receptor A saturation at 12 weeks. Started Aug 2021; status: completed.
02
Drugs
brodalumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04979520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04979520.